Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
short-chain fructooligosaccharide
- Development stage
- Unknown
- Lead developer
- Mayo Clinic
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Small Molecules, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Short-chain fructooligosaccharide (scFOS) is a prebiotic dietary fiber being evaluated by the Mayo Clinic for the prevention of pouchitis in patients with ulcerative colitis following ileal pouch-anal anastomosis (IPAA). scFOS consists of short chains of fructose molecules that are resistant to digestion in the human upper gastrointestinal tract. Upon reaching the colon, they are selectively fermented by beneficial bacteria, particularly *Bifidobacterium* species. This fermentation process promotes the production of short-chain fatty acids (SCFAs) and modulates the gut microbiome, which is hypothesized to reduce the inflammatory processes leading to pouchitis. The Mayo Clinic has conducted double-blind, placebo-controlled clinical trials to assess whether daily supplementation with scFOS chews can prevent the development of this inflammatory condition after surgical ileostomy closure.
- Other names
- scFOSshort-chain FOSprebiotic fructooligosaccharide
Beyond the preview
Go deeper on short-chain fructooligosaccharide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on short-chain fructooligosaccharide.